Zaman Anandita, Shamsuzzaman S M, Bhuiyan Farshid, Hasan Md Riasat, Saito Takashi
Dhaka Medical College, Department of Microbiology, Dhaka, Bangladesh.
Holy Family Red Crescent Medical College, Department of Physiology, Dhaka, Bangladesh.
Int J Gen Med. 2020 Nov 12;13:1093-1103. doi: 10.2147/IJGM.S273368. eCollection 2020.
Non-invasive tests can help with the diagnosis of () infection and in determining patient prognosis following eradication therapy. The aim of the study was to detect antigens in the stool in symptomatic patients and to observe changes in the antigen test results following eradication therapy.
A prospective study was conducted. Blood, urine and stool samples were collected from 62 dyspeptic patients. Anti- IgM and IgG antibodies were detected in the serum by ELISA, anti- IgG antibodies were detected in the urine by ICT and antigens were detected in the stool by ELISA. Among the 62 patients, 39 (62.90%) were positive with all three methods. These 39 patients were asked to complete a 2-week course of medication and return after 6 weeks following completion of therapy to undergo repeated tests. In total, 3 dropped out of the study.
Among the 62 dyspeptic patients, 41 (66.13%) were positive for serum IgG according to ELISA, 39 (62.90%) were positive for urine IgG according to ICT, 8 (12.90%) were positive for serum IgM according to ELISA, and 42 (67.74%) were positive for HpSA according to ELISA. After eradication therapy, 18 (50.00%) patients were positive for serum IgG, 19 (52.78%) were positive for urine IgG, 4 (11.11%) were positive for serum IgM and 5 (13.88%) were positive for HpSA. The difference in HpSA positivity before and after eradication therapy was statistically significant (P <0.05).
This study involved non-invasive procedures that can be used as first-line screening tools for the detection of active infection to observe the role of HpSA test in diagnosis and assessment of prognosis following eradication therapy for .
非侵入性检测有助于诊断（）感染，并确定根除治疗后患者的预后。本研究的目的是检测有症状患者粪便中的抗原，并观察根除治疗后抗原检测结果的变化。
进行了一项前瞻性研究。收集了62例消化不良患者的血液、尿液和粪便样本。通过酶联免疫吸附测定（ELISA）检测血清中的抗IgM和IgG抗体，通过免疫层析试验（ICT）检测尿液中的抗IgG抗体，通过ELISA检测粪便中的抗原。在这62例患者中，39例（62.90%）三种方法检测均为阳性。这39例患者被要求完成为期2周的疗程，并在治疗完成后6周返回进行重复检测。共有3例退出研究。
在62例消化不良患者中，根据ELISA检测，41例（66.13%）血清IgG呈阳性；根据ICT检测，39例（62.90%）尿液IgG呈阳性；根据ELISA检测，8例（12.90%）血清IgM呈阳性；根据ELISA检测，42例（67.74%）幽门螺杆菌粪便抗原（HpSA）呈阳性。根除治疗后，18例（50.00%）患者血清IgG呈阳性，19例（52.78%）尿液IgG呈阳性，4例（11.11%）血清IgM呈阳性，5例（13.88%）HpSA呈阳性。根除治疗前后HpSA阳性率的差异具有统计学意义（P<0.05）。
本研究采用非侵入性方法，可作为检测活动性（）感染的一线筛查工具，以观察HpSA检测在（）根除治疗后的诊断和预后评估中的作用。
